跳至主要内容
临床试验/NCT01222104
NCT01222104已完成不适用

Clinical Registry of St. Jude Medical Angio-Seal™ Vascular Closure Devices Following Interventional Radiology Procedures

Abbott Medical Devices10 个研究点 分布在 1 个国家目标入组 634 人开始时间: 2010年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
634
试验地点
10
主要终点
Rate of Major Vascular Complications

研究概览

简要总结

The purpose of this study is to collect data on the standard of care use of the St. Jude Medical (SJM) Angio Seal™ Evolution™ and V-Twist Integrated Platform (VIP) Devices in diagnostic and/or interventional radiology patient populations.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient is undergoing a diagnostic and/or interventional radiology procedure via femoral arterial access and the investigator performing the procedure would use Angio-Seal for closure as part of his/her routine care of the patient. Angio-Seal deployment will follow the standard of care for vascular closure device use and the Instructions for Use (IFU) for the device.
  • Sheath angiography prior to Angio-Seal deployment reveals appropriate anatomy and puncture location for vascular closure device deployment.

排除标准

  • Patients who are unable to provide written informed consent.

结局指标

主要结局

Rate of Major Vascular Complications

时间窗: 30 days

Collect data on patients who have undergone a diagnostic and/or interventional radiology procedure in which the St. Jude Medical (SJM) Angio-Seal Evolution or V-Twist Integrated Platform (VIP) Device was deployed, to evaluate the rate of major vascular complications out to 30 days post-procedure. The following are defined as a major vascular complication: 1. Vascular injury requiring repair via surgery, angioplasty, ultrasound guided compression, thrombin injection, or other means; 2. Permanent (unresolved at 30-day post-procedure evaluation) access site-related nerve injury or access site-related nerve injury requiring intervention; 3. Access site related bleeding requiring transfusion; 4. New ipsilateral lower extremity ischemia requiring surgical intervention; 5. Retroperitoneal bleeding; 6. Generalized infection requiring prolonged hospitalization and/or treatment with IV antibiotics; 7. Access related complication that results in extended hospital stay; 8. Death

次要结局

  • Time to Hemostasis(Procedure)
  • Rate of Minor Vascular Complications(30 days)
  • Impact of Guided Access on Use of Closure Device.(30 days)
  • Impact of Guided Access on Achieving Target Puncture Location.(30 days)
  • Rate of Major Vascular Complications (MVCs) by Guided Access Mode.(30 days)
  • Rate of Minor Vascular Complications by Guided Access Mode.(30 days)
  • Impact of Peripheral Vascular Disease (PVD) on Use of Closure Device(30 days)
  • Impact of Peripheral Vascular Disease (PVD) on Achieving Hemostasis by Device(30 days)
  • Rate of Major Vascular Complications (MVC) by Presence of Peripheral Vascular Disease (PVD)(30 days)
  • Rate of Minor Vascular Complications by Presence of Peripheral Vascular Disease (PVD)(30 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验